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Abstract: 211/250 17 
The human gamma herpesvirus Epstein-Barr virus (EBV; HHV4), infects most adults and is an 18 
important contributor to the development of many types of lymphoid and epithelial 19 
cancers. Essential contributions of viral genes to viral replication are known, but the 20 
potential contributions of cell genes are less well delineated. A key player is the viral protein 21 
Zta (BZLF1, ZEBRA, Z). This sequence-specific DNA-binding protein can disrupt EBV latency 22 
by driving the transcription of target genes and by interacting with the EBV lytic origin of 23 
 2 
replication. Here we used an unbiased proteomics approach to identify the Zta-interactome 24 
in cells derived from a Burkitt’s lymphoma. Isolating Zta and associated proteins from 25 
Burkitt’s lymphoma cells undergoing EBV replication, followed by Tandem Mass Tag (TMT) 26 
mass spectrometry resulted in the identification of thirty-nine viral and cellular proteins 27 
within the Zta interactome. An association of Zta with the cellular protein NFATc2 was 28 
validated in independent experiments. Furthermore, the ability of Zta to attenuate the 29 
activity of an NFAT-dependent promoter was shown which suggests a functional 30 
consequence for the association. The expression of Zta is itself regulated through NFAT 31 
activity, suggesting that Zta may contribute to a feed-back loop that would limit its own 32 
expression, thus aiding viral replication by preventing the known toxic effects of Zta 33 
overexpression.  34 
Data are available: ProteomeXchange PXD013727. 35 
 36 
Importance: 124/150 37 
Epstein-Barr virus, infects most people across the world and causes several kinds of cancer. 38 
Zta is an important viral protein that makes the virus replicate by binding to its DNA and 39 
turning on the expression of some genes. We used a sensitive, unbiased approach to isolate 40 
and identify viral and cellular proteins that physically interact with Zta. This revealed thirty-41 
nine viral and cellular proteins. We found that one protein termed NFATc2, was already 42 
known to be important for a very early step in viral replication. We identify that once this 43 
step has occurred, Zta reduces the effectiveness of NFATc2 and suggest that this is 44 
 3 
important to prevent cells from dying before viral replication is complete and the mature 45 
virus is released from the cells.  46 
 47 
Introduction 48 
Epstein-Barr virus (EBV) establishes life-long latency in memory B-cells following primary 49 
infection (1, 2). The virus is reactivated from latency to undergo lytic replication when the 50 
infected B-cell is activated following the presentation of its cognate antigen (3-5). A cascade 51 
of viral gene expression ensues resulting in viral genome replication, packaging and egress 52 
from cells. Zta (BZLF1, EB1, ZEBRA, Z), a viral transcription factor that often works in consort 53 
with a second viral transcription factor Rta (BRLF1), activates the expression of many of 54 
these lytic cycle genes (6).  Genome-wide analyses of Zta and Rta binding sites reveal many 55 
viral genes that are direct targets for transactivation (7-9). In addition to this important role, 56 
Zta binds to the lytic origin of viral genome replication (OriLyt) (7, 8, 10-12). Lytic genome 57 
replication is achieved by the action of additional six viral genes (13), with potential 58 
additional contributions from cellular proteins. In addition to binding to the viral genome at 59 
OriLyt, Zta interacts with some viral protein components of the EBV replisome (13), 60 
potentially facilitating the formation of the functional replisome at OriLyt.  61 
Viral replication is inextricably linked to the cellular environment, but the precise 62 
contributions of cellular proteins to EBV replication are unclear. Unbiased proteomics 63 
screens have identified many cellular proteins that interact with Zta. For mtSSB (14), 53BP1 64 
(15), TORC2 (16) and INO80 (17),  evidence from gene knock-down approaches shows that 65 
each gene contributes to the ability of EBV to replicate within a cell.  66 
 4 
 67 
Here we sought to identify cellular proteins that interact with full-length Zta protein during 68 
authentic viral lytic replication, following the application of a physiologically relevant 69 
stimulus to latently infected B-cells. We anticipated that this may identify cellular proteins 70 
that contribute to any stage of EBV lytic replication, including but not exclusive to known 71 
transcription and DNA replication functions of Zta. This unbiased screen identified thirty-72 
nine candidate proteins: seven viral and thirty-two cellular. The validity of the data set is 73 
shown by the inclusion of previously identified targets of Zta and our demonstration of the 74 
relevance of a novel component (NFATc2) for efficient EBV lytic replication.  75 
 76 
Results 77 
Isolation of the Zta interactome in Akata BL cells 78 
An EBV positive Burkitt’s lymphoma cell line (Akata), that harbours a latent EBV genome, 79 
was stimulated to enter lytic replication by cross-linking the surface B cell receptor (BCR) 80 
using anti-human immunoglobulin IgG, to mimic the physiologically relevant event of 81 
antigen recognition (3). Entry into lytic cycle was demonstrated by evaluating the expression 82 
of Zta protein (Fig. 1A) and changes in the abundance of the EBV genome (Fig. 1B). Analysis 83 
of the total population of cells entering early and late lytic cycle was also monitored by 84 
fluorescent activated cell sorting for Zta and gp110 (BALF4; VCA) respectively (data not 85 
shown).  86 
 87 
The major challenge to isolating the Zta interactome lie with its strong DNA-association. 88 
Native cell lysis results in low yields of Zta, yet harsh conditions are likely to dissociate the 89 
sought-for interactions. Zta-bound DNA has been previously extracted from cells combining 90 
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the use of an in-cell cross-linking agent, formaldehyde, followed by a harsh ionic detergent 91 
(8, 18, 19). Here we sought a compromise approach. We used dithiobis-succinimidyl 92 
propionate) (DSP), a bi-functional amine-reactive cross-linker with a spacer arm of (12Å) to 93 
undertake in-cell cross-linking of proteins. This promoted the formation of high molecular 94 
weight Zta-complexes, which can be released by subsequent reduction (data not shown). 95 
Following cross-linking, proteins were extracted into a non-denaturing buffer from the 96 
insoluble chromatin by digesting the chromatin with DNase.  97 
 98 
This approach was used to isolate the Zta-interactome from Akata cells undergoing lytic 99 
replication. Two controls were designed to enable reliable identification of the Zta 100 
interactome: extracts from latent Akata cells, precipitated with Zta antibody; and extracts 101 
from Akata cells induced to enter lytic replication, precipitated with a control antibody. 102 
Repeat experiments were undertaken in triplicate (Fig. 1C). Each of the nine samples were 103 
labelled with a different tandem mass tag (TMT) -reagent and processed for mass 104 
spectrometry. Proteins that were enriched >2 fold compared to each control (p≤0.05) were 105 
classified as specifically interacting with Zta in the lytic cycle (Fig. 1D).  106 
 107 
Analysis of the proteins in the Zta-interactome 108 
As anticipated, Zta was the highest scoring protein identified during the proteomic analysis 109 
(Fig. 1D). In addition, seven viral proteins displayed reproducibly (p≤0.05) high ratios in the 110 
Zta immunoprecipitation compared to either control (Table 1). Of these, both BGLF4 and 111 
BALF5 have been shown to interact with Zta previously (10, 20, 21). The identification of 112 
these proteins provides a validation of the experimental approach.  113 
 114 
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Thirty-two cellular proteins were also reproducibly (p≤0.05) enriched more than two-fold in 115 
the Zta precipitation when compared to both controls (Table 2). Analysis of common Gene 116 
Ontology (Biological Processes) revealed an enrichment for proteins involved in 117 
transcription, the nucleus and nucleoplasm (Fig. 2 and Table S1).  Of these functionally 118 
related proteins, one was chosen for further analysis NFATc2. 119 
 120 
Contribution of NFATc2 to EBV replication 121 
NFATc2 encodes a transcription co-factor that is activated through calcium mediated signal 122 
transduction following dephosphorylation by calcineurin. It acts together with the AP1 123 
transcription factor to activate gene expression via a composite DNA element ARRE2 (22-124 
24). Using immunoprecipitation with non-cross-linked protein extracts from Akata cells 125 
induced to initiate EBV lytic cycle, we demonstrate the co-precipitation of NFATc2 with Zta 126 
antibodies (Fig. 3A). To probe the specificity of the interaction further, we undertook 127 
additional immune precipitation experiments with two other nuclear DNA binding proteins 128 
expressed in B-cells, EBF1 and LEF1. Neither of these co-precipitated NFATc2 protein (Fig. 129 
3B-C). 130 
 131 
To explore the contribution of NFATc2 to his-Zta mediated transcriptional regulation, we 132 
used a Zta-responsive viral reporter, BHFL1p luciferase (Fig. 4). This promoter is 133 
transactivated by over 200-fold when introduced into cells with a hisZta expression vector. 134 
When PMA and ionomycin are added to stimulate the activation of NFATc2/AP1, there is 135 
little impact on either basal transcription or Zta-mediated activation (Fig. 4 A-C).  This 136 
suggests that the NFATc2 interaction with Zta does not result in an alteration of the 137 
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transactivation potential of Zta. To explore this further, the endogenous abundance of 138 
NFATc2 was decreased using a smart Si RNA pool against NFAT genes and the impact on Zta-139 
mediated activation of BHLF1p determined. Although the smart pool reduced NFATc2 140 
protein abundance by 66%, there was no consequent decrease in the ability of Zta to 141 
activate gene expression (Fig. 4 D-F).   142 
 143 
An NFAT reporter assay was used to ask the reciprocal question, whether an NFAT-144 
dependent promoter was impacted by the expression of hisZta (Fig. 5A). The NFAT reporter 145 
pGL3 NFAT-luciferase was introduced into DG75 B-cells with control SiRNA or the smart Si 146 
RNA pool against NFAT genes. As anticipated, the combination of both Ionomycin and PMA 147 
lead to a substantial increase in transcriptional activation of the NFAT reporter. The 148 
inclusion of the NFAT Si RNA smart pool resulted in a ~50% reduction in the expression of 149 
both NFATc1 and NFATc2. A similar decrease in Ionomycin and PMA driven promoter 150 
activity was observed when the NFAT smart Si RNA pool was co-expressed (Fig. 5 B-C). This 151 
confirms that the Ionomycin and PMA stimulation of the pGL3 NFAT-luciferase promoter is 152 
regulated by NFAT in these cells.  153 
 154 
The inhibitor FK506 blocks the activation of calcineurin and JNK (25), thereby inhibiting 155 
activation of NFATc2/AP1; this was used here to identify calcineurin- and JNK-dependent 156 
regulatory events. The increased NFAT reporter promoter activity stimulated by Ionomycin 157 
and PMA was negated by the addition of FK506 as expected (Fig. 5D). Co-transfection of 158 
hisZta with the NFAT reporter resulted in a rise in basal promoter activity. As AP1 sites have 159 
some similarity of sequence with ZREs, we questioned whether Zta may act directly through 160 
ARRE2. We analysed the composite NFAT/AP1 site in this reporter for known Zta binding 161 
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sites (26) and we evaluated the potential for Zta to bind to the element using in vitro DNA 162 
binding assays (Fig. 6). Neither line of investigation provided support for a direct Zta DNA-163 
interaction with this promoter. Zta also interacts with components of the basal 164 
transcriptional machinery including the TATA-binding protein TFIID (27), and we suggest 165 
that the increase in basal expression may result from this.  When the impact of hisZta 166 
expression on promoter activation observed following ionomycin and PMA was assessed, 167 
hisZta was shown to significantly and substantially reduce this activation by 25 fold (Fig. 5C-168 
D). The impact of hisZta expression is also reflected when considering the ionomycin and 169 
PMA stimulated cells and comparing the difference of NFAT-dependent promoter activity in 170 
the presence and absence of hisZta expression where a significant reduction in activity is 171 
also observed.  172 
 173 
Discussion 174 
The identification of the Zta interactome opens a new avenue of understanding of Zta 175 
function during the EBV lytic replication cycle. The identification of two previously known 176 
targets of Zta (BGLF4 and BALF5) provides robust confirmation of the relevance of these 177 
targets and the additional proteins.  178 
 179 
Of the five novel viral proteins, three are found in the viral capsid. The portal protein, 180 
BBRF1, is a homologue of HSV-1 UL6, which is required for the encapsulation and cleavage 181 
of the viral genome. Specifically, the deletion of BBRF1 from the EBV genome has been 182 
shown to result in 'empty' capsids containing no viral genome (28) and transmission 183 
electron microscopy of BBRF1 revealed the formation of a self-assembling structure 184 
consistent with other herpesvirus portals (29). Two further capsid proteins BVRF2, a 185 
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protease, and BcLF1, the major capsid protein, are both required for the EBV capsid 186 
assembly (30). Interaction of Zta with these three capsid proteins suggested that, in addition 187 
to its well-characterized role in events leading to EBV genome replication, Zta might have 188 
additional roles downstream of genome replication, relating to the assembly or function of 189 
the capsid.  190 
 191 
The importance of calcium signalling to the disruption of latency by reactivation of the EBV 192 
lytic cycle following immunoglobulin stimulation is well established; inhibitors of critical 193 
aspects of Ca2+-mediated signal transduction pathways, cyclosporin A (CsA) and Tarcolimus 194 
(FK506) that converge on the inhibition of the Ca2+-dependent phosphatase calcineurin, 195 
both block EBV lytic reactivation (31). Calcium signalling acts on the BZLF1 promoter 196 
through many routes including the actions of TORC2 and MEF2 (32). Recently, enhanced 197 
EBV lytic cycle reactivation was identified in cancer-associated EBV strains and a sequence 198 
variation within the BZLF1 promoter that forms a functional response element for the NFAT 199 
transcription factor was found to contribute an additional route for activation through 200 
calcium signal transduction (33).  201 
 202 
We were therefore intrigued to identify NFATc1 and NFATc2 as members of the Zta 203 
interactome. NFAT has four family members, that are activated by dephosphorylation by 204 
the Ca2+-dependent phosphatase calcineurin, resulting in nuclear translocation followed by 205 
direct interaction with DNA response elements. The obvious approach to questioning the 206 
role of the Zta-NFAT interaction in EBV lytic cycle is to inhibit the expression of NFAT. The 207 
calcineurin inhibitor FK506 suggests a route to question the contribution of NFATs to Zta 208 
function. However, the first step in EBV reactivation, activation of Zta expression, is 209 
 10 
controlled through Ca2+-dependent signal transduction and so inhibiting calcineurin-210 
dependent signal transduction with FK506 will both inhibit Zta activation and all subsequent 211 
Zta-dependent events (31); we confirmed that this was so for Akata cells (data not shown). 212 
We therefore used simple promoter-reporters to dissect the potential for cross-talk 213 
between Zta and the NFAT transcription factors. After validating that the PMA and 214 
ionomycin stimulation of the NFAT-dependent promoter is reliant on NFAT expression in 215 
these cells, we found that Zta attenuates NFAT-mediated activation.  In contrast, NFAT does 216 
not impact on Zta-mediated activation through ZREs. This approach revealed that the 217 
impact of NFAT-Zta cross-talk is unidirectional. We propose a model whereby the 218 
attenuation of NFAT-mediated activation by Zta occurs through the protein-protein 219 
interaction between Zta and NFAT that we identified using TMT-mass spectrometry (Fig. 7). 220 
 221 
The attenuation of NFAT-mediated gene activation by Zta poses a conundrum when 222 
considering the contribution of NFAT to EBV lytic reactivation. We know that inhibition by 223 
the calcineurin inhibitor FK506 prevents EBV lytic cycle reactivation, implying a positive role 224 
for calcineurin-dependent targets such as NFAT during EBV lytic reactivation. However, the 225 
attenuation of NFAT-mediated gene activation by Zta suggests that NFAT activity may be 226 
obstructive to EBV lytic cycle.  A solution lies with careful consideration of the order of the 227 
events during EBV reactivation and lytic cycle. It is known that Zta expression can have 228 
negative impacts on cell viability and that during EBV lytic cycle the expression of Zta is 229 
coupled to an ordered co-expression of the anti-apoptotic viral protein v-BCL2 (BHRF1) (34). 230 
Indeed, there is evidence that Zta (BZLF1) mRNA expression is limited during the EBV lytic 231 
cycle; abundance of the transcript is known to first peak then fall following immunoglobulin 232 
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cross-linking (35). We propose that we have identified a negative feedback-loop that acts to 233 
fine-tune Zta expression during EBV lytic cycle and that this is mediated by the ability of Zta 234 
to attenuate the NFAT-activity. The Ca2+-dependent signal transduction that initiates EBV 235 
lytic reactivation stimulates NFAT transcription factors to activate the BZLF1 promoter 236 
through the several DNA elements including the NFAT response element. This promotes the 237 
expression of Zta protein, which acting through interactions with its DNA-response elements 238 
directly re-programmes EBV and cellular gene expression. As Zta levels rise, we suggest that 239 
the interaction between Zta with NFATc2 results in attenuation of NFAT-dependent 240 
transcription leading to reduced Zta expression. Together this maintains the Zta abundance 241 
in cells within the required, yet tolerated zone. The direct interactions between Zta and 242 
NFATc2 suggest a novel molecular mechanism to fine-tune the expression of Zta.  243 
 244 
Materials and Methods 245 
Cells and transfections. Akata Burkitt’s Lymphoma cells (4) and DG75 cells (36) were 246 
maintained in RPMI 1640 medium supplemented with 10% FBS, 100 units/ml penicillin, 100 247 
μg/ml streptomycin and 2 mM L-glutamine (Fisher Scientific) at 37°C with 5% CO2. To induce 248 
EBV lytic cycle in Akata cells, cells were re-suspended at 2 x 106 cells/ml in media and anti-249 
human IgG (Dako) was added to 0.13 % (v/v) of the final volume, then incubated for 24 250 
hours. 251 
 252 
For promoter-reporter experiments, electroporation (Biorad) was used to introduce 5μg of 253 
BHLF1-luciferase, or GL3NFAT-luciferase together with 5μg of pcDNA3 or pcDNA3-hisZta 254 
plasmids into 1 x 107 DG75 cells. 48 hours later, 90μl of passive cell lysis buffer (Promega) 255 
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was added to the cell pellets and incubated 30 minutes on ice, then 30 minutes at room 256 
temperature. Then cell lysates were centrifuged and the supernatant was transferred to 257 
clean tubes. 10μl of triplicate samples were pipetted into a white 96-well plate. A Glomax 258 
(Promega) multi-detection plate reader with an auto sampler, dispensed 50μl of luciferase 259 
activation reagent (Promega) per well, and read output light for 10 seconds with a delay for 260 
2 seconds after adding the reagent. The protein concentration in the lysates was 261 
determined using a bicinchoninic acid (BCA) assay (Pierce). The concentration of each lysate 262 
used to normalise the luciferase activity. 263 
 264 
Either a smart pool of SiRNA directed against NFATc1 and c2 or the non-targeting siRNA 265 
pool #1 (Dharmacon) was introduced into DG75 cells. No targeting smartpool #1 consists of 266 
UAGCGACUAAACACAUCAA, UAAGGCUAUGAAGAGAUAC, AUGUAUUGGCCUGUAUUAG; 267 
NFATc1 targeting smartpool UCAGAAACUCCGACAUUGA, GGACAGCUAUCCGGUCGUG, 268 
GUUGAGAUCCCGCCAUUUC, AGGAAGAACACACGGGUAC; NFATc2 targeting smartpool 269 
CCAAUAAUGUCACCUCGAA, GCAGAAUCGUCUCUUUACA, GCGGGGAUCUUGAAGCUUA, 270 
UCAUGUACUGCGAGAAUUU. The concentration of Non-Targeting siRNA pool #1 was 271 
200μM, Human NFATC1 siRNA 100μM and Human NFATc2 siRNA 100μM.  250ng of pcDNA3 272 
or pcDNA3-hisZta expression vectors and 250ng of BHLF1-luciferase were delivered at the 273 
same time. The Neon transfection system (100μl Neon kit) was used in this experiment. 5 x 274 
106 cells were resuspended in 104μl Buffer T. 6μl DNA and RNA mix in each condition was 275 
prepared before adding to the cells. Electroporation was performed at 1300V, 30 msec, and 276 
1 pulse in 100μl Neon tip. Whole media without antibiotics was used for culturing the cells. 277 
24 hours post-transfection, ionomycin (final concentration 1μM) and PMA (final 278 
concentration 20ng/ml) were added as indicated, after another 48 hours, cells were 279 
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harvested and washed by D-PBS. Then 1/10 of the cells were used for western blotting and 280 
the rest of the cells were used for luciferase assay. 281 
 282 
Cell viability was determined using Alamar Blue (Invitrogen). Following an overnight 283 
incubation, fluorescence was measured using a Glomax (Promega) plate reader with an 284 
excitation wavelength of 520nm and an emission at 580-640nm. 285 
 286 
EBV viral load was determined using an established assay (38).  287 
 288 
An inhibitor of Calcineurin FK506 (Sigma) was solubilised in water. 289 
 290 
Proteins 291 
Immunoprecipitations were carried out using lysates derived from 5 x 107 Akata cells 292 
without cross-linking of cells. Lysis in cell lytic reagent (Sigma) and DNAse digestion were 293 
undertaken, as for proteomics preparation. However, the anti-Zta goat antibody SCZ (Santa 294 
Cruz) was added overnight followed by addition of protein-G dynabeads without prior cross-295 
linking of the antibody to the beads. For LEF1 immunoprecipitations rabbit LEF1 #2286s 296 
from CST was used and for EBF1, mouse EBF Antibody (C-8): sc-137065 (Santa Cruz) was 297 
used. Following washing precipitated proteins were analysed by western blot with 298 
monoclonal antibodies specific for NFATc2 (Santa Cruz) and the precipitated proteins.  299 
 300 
For western blot analysis, protein samples were separated in 10% Bis-Tris NuPAGE gel in 301 
morpholinepropanesulfonic buffer (MOPS). Following blocking for non-specific binding, the 302 
membrane was incubated with primary antibodies at 4°C overnight, including BZ1 antibody 303 
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(a kind gift from Martin Rowe, mouse 1:200), Actin antibody (Sigma, Rabbit 1:1000), NFATc2 304 
(Santa Cruz, mouse, 1:200) and GFP antibody (Invitrogen, rabbit, 1:1000). Following washing 305 
in PBS-Tween (0.1%), incubation continued with either fluorescent or enzyme-linked 306 
secondary antibodies. Donkey anti-rabbit (Licor, 800CW, 1:5000-1:10,000), goat anti-mouse 307 
(Licor, 680RD, 1:5000-1:10,000), anti-multi species conjugated HRP (VeriBlot Abcam 1:1000) 308 
were incubated for 1 hour at room temperature. The fluorescent signal was detected at 309 
either 700nm or 800nm channel by the Odyssey Fc system. The HRP-linked signal was 310 
detected with the Westernsure ECL substrate (Licor) and the Odyssey Fc imager (LI-COR). 311 
 312 
Proteomics and immunoprecipitations 313 
For each replicate, 1 x 108 Akata cells were concentrated to 1 x 107 cells/ml and were cross-314 
linked following addition of 0.2mM DSP (Thermo Scientific) for 30 minutes at room 315 
temperature. The reaction was stopped by the addition of Tris solution to a final 316 
concentration of 50mM and incubated for 15 minutes, then cells were washed with D-PBS 317 
(Gibco). The cells were re-suspended in CellLytic MT cell lysis reagent (Sigma) for 10 minutes 318 
at 4°C. After centrifugation, the nuclear pellets were then re-suspended in lysis reagent 319 
(Sigma) with the addition of 250U/ml of Benzonase (Sigma). The nuclear extracts were then 320 
diluted in IP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 321 
8.0, 167 mM NaCl). 10µg SCZ Zta antibody or control goat IgG were added to 25µl of protein 322 
G-dynabeads and cross-linked following the addition of bis(sulfosuccinimidyl)suberate (BS3) 323 
(Thermo Scientific). These were then incubated with the nuclear extracts and overnight at 324 
4°C on a rotating wheel. Beads were washed by low salt, high salt, lithium buffers as 325 
described previously for Chromatin precipitation  (39) and finally washed in 10 mM Tris/Cl 326 
pH 7.5; 150 mM NaCl; 0.5 mM EDTA. The final wash buffer was removed and the beads 327 
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were resuspended in 50mM triethyl ammonium bicarbonate prior to reduction (10mM 328 
TCEP, 55°C, 1h), alkylation (18.75mM iodoacetamide, ambient, 30min) and digestion with 329 
trypsin (2.5µg trypsin per sample; 37°C, overnight).  Proteins were eluted in 2 X Laemmli 330 
sample buffer for 10 min at 95 °C. Samples on the beads were reduced, alkylated and 331 
digested with trypsin (2.5µg trypsin per sample; 37°C, overnight).  The resulting peptides 332 
were labelled with Tandem Mass Tag (TMT) ten plex reagents according to the 333 
manufacturer’s protocol (Thermo Fisher Scientific) and the labelled samples pooled. The 334 
pooled sample was evaporated to dryness and resuspended in buffer A (20mM ammonium 335 
hydroxide, pH 10) prior to fractionation by high pH reversed-phase chromatography using 336 
an Ultimate 3000 liquid chromatography system (Thermo Fisher Scientific).  In brief, the 337 
sample was loaded onto an XBridge BEH C18 Column (130Å, 3.5 µm, 2.1 mm X 150 mm, 338 
Waters, UK) in buffer A and peptides eluted with an increasing gradient of buffer B (20 mM 339 
Ammonium Hydroxide in acetonitrile, pH 10) from 0-95% over 60 minutes. The resulting 340 
fractions (four in total) were evaporated to dryness and resuspended in 1% formic acid prior 341 
to analysis by nano-LC MSMS using an Orbitrap Fusion Tribrid mass spectrometer (Thermo 342 
Scientific). 343 
 344 
High pH RP fractions were further separated using an Ultimate 3000 nanoHPLC system in 345 
line with an Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific).  In brief, 346 
peptides in 1% (vol/vol) formic acid were injected onto an Acclaim PepMap C18 nano-trap 347 
column (Thermo Scientific). After washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) 348 
formic acid, peptides were resolved on a 250 mm × 75 μm Acclaim PepMap C18 reverse 349 
phase analytical column (Thermo Scientific) over a 150 min organic gradient, using 7  350 
gradient segments (1-6% solvent B over 1min., 6-15% B over 58min., 15-32%B over 58min., 351 
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32-40%B over 5min., 40-90%B over 1min., held at 90%B for 6min and then reduced to 1%B 352 
over 1min.) with a flow rate of 300 nl min−1.  Solvent A was 0.1% formic acid and Solvent B 353 
was aqueous 80% acetonitrile in 0.1% formic acid.  Peptides were ionized by nano-354 
electrospray ionization at 2.0kV using a stainless-steel emitter with an internal diameter of 355 
30 μm (Thermo Scientific) and a capillary temperature of 275°C.  356 
 357 
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer (Thermo 358 
Scientific), controlled by Xcalibur 2.0 software (Thermo Scientific) and operated in data-359 
dependent acquisition mode using an SPS-MS3 workflow.  FTMS1 spectra were collected at 360 
a resolution of 120 000, with an automatic gain control (AGC) target of 200 000 and a max 361 
injection time of 50ms. Precursors were selected with an intensity threshold of 5000, 362 
according to charge state (to include charge states 2-7) and with monoisotopic precursor 363 
selection. Previously interrogated precursors were excluded using a dynamic window (60s 364 
+/-10ppm). The MS2 precursors were isolated with a quadrupole mass filter set to a width 365 
of 1.2m/z. ITMS2 spectra were collected with an AGC target of 10 000, max injection time of 366 
70ms and CID collision energy of 35%. For FTMS3 analysis, the Orbitrap was operated at 50 367 
000 resolution with an AGC target of 50 000 and a max injection time of 105ms.  Precursors 368 
were fragmented by high energy collision dissociation (HCD) at a normalised collision energy 369 
of 60% to ensure maximal TMT reporter ion yield.  Synchronous Precursor Selection (SPS) 370 
was enabled to include up to 5 MS2 fragment ions in the FTMS3 scan. 371 
 372 
The raw data files were processed and quantified using Proteome Discoverer software v2.1 373 
(Thermo Scientific) and searched against the UniProt Human database (140000 entries) plus 374 
EBV_proteome_B95_8 (UO000153037) and EBV_Proteome_GD1 (UP000103223) sequences 375 
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using the SEQUEST algorithm.  Peptide precursor mass tolerance was set at 10ppm, and 376 
MS/MS tolerance was set at 0.6Da.  Search criteria included oxidation of methionine 377 
(+15.9949) as a variable modification and carbamidomethylation of cysteine (+57.0214) and 378 
the addition of the TMT mass tag (+229.163) to peptide N-termini and lysine as fixed 379 
modifications. Searches were performed with full tryptic digestion and a maximum of 2 380 
missed cleavages were allowed.  The reverse database search option was enabled and all 381 
data was filtered to satisfy false discovery rate (FDR) of 5%.     382 
 383 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange 384 
Consortium via the PRIDE [1] partner repository with the dataset identifier PXD013727. 385 
 386 
The Gene Ontology (GO) analysis were undertaken through from The Database 387 
for Annotation, Visualization and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/) 388 
(40). 389 
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  515 
Figure Legends 516 
Figure 1. Identification of the Zta-interactome in Akata cells undergoing EBV lytic 517 
replication. 518 
Akata cells were induced to initiate EBV replication by exposure to IgG for 24 hours.  519 
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A. Zta protein expression was validated by western blot analysis with the antibodies for 520 
the indicated proteins. The migration of molecular weight markers (kD) is shown on 521 
the left. 522 
B. Induction of EBV lytic replication was assessed using Q-PCR to determine the change 523 
in EBV genome load in the cells. ** p≤0.01. 524 
C. The immunoprecipitates for each of the triplicates in each arm of the study were 525 
analyzed by western blot for Zta protein.  526 
D. A DSP-crosslinked protein extract was isolated following treatment with DNAse. 527 
Following immunoprecipitation with control of Zta-specific antibodies, proteins were 528 
subject to TMT-labelling and mass spectrometry. The abundance changes are shown 529 
on a scatter plot relative to each control (log2). Those shown in green were enriched 530 
≥2 fold for with respect to either control. 531 
E.  532 
Figure 2. Zta interactome gene ontology analysis.  533 
Gene ontology analysis of the 37 human proteins found that interact with Zta by mass 534 
spectrometry. The components of the most enriched group are shown in the chart (with p-535 
value ≤0.001). 536 
 537 
Figure 3. Association of NFATc2 with Zta in cells.  538 
Akata cells were induced to lytic cycle for 24 hours following exposure to anti-IgG and 539 
proteins were extracted and analysed as ‘Input’. Extracts were subject to 540 
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immunoprecipitation with the indicated antibodies and isotype controls then analysed by 541 
western blotting for the proteins shown.  542 
A. Immunoprecipitation antibody Zta  543 
B. Immunoprecipitation antibody EBF1 544 
C. Immunoprecipitation antibody LEF1 545 
The migration of molecular weight markers (kD) is shown on the left. 546 
 547 
Figure 4. No impact of calcium signaling pathway on transcriptional activation by Zta in B-548 
cells.  549 
DG-75 B-cells were transfected with a Zta-reporter plasmid (BHLF1-luciferase) with and 550 
without co-transfection of expression vectors for his Zta.  551 
A. The ZRE driven reporter BHLF1-luciferase is shown with the location of six ZREs 552 
indicated (as filled boxes). 553 
B. Calcium signaling was stimulated or not through the addition of ionomycin/PMA. 48 554 
hours later, cells were harvested for luciferase assay and western blot analysis. 555 
Luciferase reporter assays were undertaken and the activation by hisZta or the 556 
control vector, was normalized to total protein concentration. Error bars represent 557 
the mean of triplicate readings ± SD.  558 
C. Western blot analysis of Zta in B.  559 
D. BHLF1-luciferase was co-transfected with Zta or control vector, and NFATc1 and 560 
NFATc2 siRNA smart pool or non-targeting control siRNA by Neon electroporation in 561 
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DG-75 cells. Luciferase reporter assays were undertaken and the activation of hisZta 562 
and control vector, normalized to total protein are shown.  563 
E. Western blot analysis of the indicated proteins in D.  564 
F. Following quantitation, the expression of NFATc1 is shown in black and for NFATc2 in 565 
grey. 566 
Error bars represent the mean of triplicate readings ± SD.  567 
Figure 5. Zta impact on NFAT transcription activity.  568 
pGL3-IL2 NFAT luciferase reporter construct was co-transfected with hisZta, a control vector 569 
or Si RNA pools into DG75 cells. Ca2+ signaling was activated by ionomycin/PMA immediately 570 
after transfection with the addition of the inhibitor FK506 as indicated. After 48 hours, cells 571 
were harvested for luciferase reporter and western blot analysis.  572 
A. The luciferase reporter promoter is shown. The NFAT ARRE2 elements are indicated 573 
as filled boxes.  574 
B. Luciferase assay showing the fold change in activity after Ionomycin/PMA 575 
stimulation and impact of NFAT c1 and NFATc2 Si RNA.  576 
C. Western blot showing the impact on NFATc1 and NFATc2 expression level.  577 
D.  Luciferase assay showing the fold change in activity after Ionomycin/PMA 578 
stimulation, FK506 inhibition and impact of Zta expression. 579 
E. Western blot showing Zta expression. 580 
Error bars represent the mean of triplicate reads ± standard deviation (*) indicates p<0.05; 581 
(**) indicates p<0.01; (*) indicates p≤0.05. 582 
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  583 
Figure 6. Zta bZIP domain interaction with a ZRE and the NFAT/ARRE2 element.  584 
The ability of GFP-tagged Zta bZIP domain to interact with the ARRE2 element was 585 
compared to a ZRE element by electrophoresis mobility shift assay (EMSA).  586 
A. The DNA sequence of each probe is shown with the known ZRE (underscored), the NFAT 587 
element (bold) and the AP1 site (boxed) shown. 588 
B. GFP and GFP-bZIP Zta proteins were produced and 1 μg analysed by staining. 589 
C. The interaction of each GFP and GFP-bZIP Zta protein with the indicated ZREs are shown.  590 
The relative level of complex is shown below each GFP-bZIP Zta lane. 591 
 592 
 Figure 7. Impact of ionomycin, PMA and Zta on the IL2 promoter. 593 
The IL2 promoter and one ARRE2 element is shown (dark grey box) with location of 594 
transcription factors (NFATc2 grey cube; AP1 filled circle; Zta open circle).  595 
B. Following stimulation with ionomycin and PMA, transcription is activated through 596 
the interaction of NFATc2 and AP1 at the ARRE2 element. This is blocked by the 597 
FK506. 598 
C. Following expression of Zta, transcription is activated to a lesser extent through an 599 
indirect means that is not inhibited by FK506. 600 
Combining stimulation with ionomycin and PMA and expression of Zta, transcription is 601 
activated to an intermediate extent. FK506 reduces the expression to the level seen when 602 
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Zta is activation alone. Interaction of Zta with NFATc2 may account for the reduction in 603 
impact of ionomycin and PMA stimulation. 604 
 605 
Table 1. Viral proteins in the Zta-interactome in Akata cells undergoing EBV lytic 606 
replication. 607 
EBV proteins identified as part of the Zta-interactome in Akata cells are shown, together 608 
with the fold change in abundance relative to each control (p≤0.05), the total number of 609 
identified peptide spectra matched (psm) for the protein and the brief description of the 610 
gene function.  611 
 612 
Gene name Description 
Unique 
peptide 
# PSMs 
Ratio: 
compared 
to non-lytic 
 Ratio: 
compared 
to control 
antibody 
BBRF1 Portal protein 1 1 28.82 10.21 
BVRF2 Capsid scaffolding protein 12 15 13.12 4.88 
BGLF4 Serine/threonine-protein kinase 5 5 11.54 2.28 
BALF2 Major DNA-binding protein 17 18 11.77 2.26 
BcLF1 Major capsid protein 17 18 10.72 2.42 
BALF5 DNA polymerase 5 5 8.81 2.40 
BMLF1 
mRNA export factor ICP27 
homolog 
6 6 6.57 2.35 
  613 
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Table 2. Cell proteins in the Zta-interactome in Akata cells undergoing EBV lytic 614 
replication. 615 
Cell proteins identified as part of the Zta-interactome in Akata cells are shown, together 616 
with the fold change in abundance relative to each control p≤0.05), the total number of 617 
identified peptide spectra matched (psm) for the protein and the brief description of the 618 
gene function.  619 
Gene name Description 
Unique 
peptide 
# PSMs 
Ratio: 
compared to 
non-lytic 
Ratio: 
compared 
to control 
antibody 
FAM96B 
Mitotic spindle-associated MMXD 
complex subunit MIP18 
2 2 13.35 13.55 
TMED9 
Transmembrane emp24 protein 
transport domain containing 9 
1 2 8.8 6.88 
TIPRL TIP41-like protein 2 2 7.74 7.14 
NCOA5 Nuclear receptor coactivator 5 20 34 6.65 3.92 
MMS19 
MMS19 nucleotide excision repair 
protein homolog 
7 7 6.47 8.05 
TMED10 
Full-length cDNA 5-PRIME end of 
clone CS0DF013YM24 of Fetal 
brain of Homo sapiens (Human) 
variant (Fragment) 
2 2 6.33 5.37 
FGFR2 Adenosylhomocysteinase 2 2 5.52 5.39 
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CIAO1 
Probable cytosolic iron-sulfur 
protein assembly protein CIAO1 
2 2 4.51 8.39 
NFATC2 
Nuclear factor of activated T-cells, 
cytoplasmic 2 
6 6 3.37 2.8 
HSPA8 
Heat shock cognate 71 kDa 
protein (Fragment) 
15 70 3.23 2.13 
ARID1A 
AT-rich interactive domain-
containing protein 1A 
4 4 3.09 3.23 
RUNX3 Runt-related transcription factor 1 1 2.96 2.55 
ADAMTSL1 ADAMTS-like protein 1 1 1 2.89 3.71 
HSPA9 Stress-70 protein, mitochondrial 9 24 2.83 2.13 
TLE3 
Transducin-like enhancer protein 
3 
4 4 2.65 2.48 
NFATC1 
Nuclear factor of activated T-cells, 
cytoplasmic 1 
5 6 2.63 2.35 
TMED2 Transmembrane emp24 domain-
containing protein 2 
2 2 2.62 2.43 
TAF6 Transcription initiation factor 
TFIID subunit 6 
1 1 2.53 2.37 
SRSF9 Serine/arginine-rich splicing 
factor 9 
6 8 2.53 2.13 
HMG20A High mobility group protein 20A 2 2 2.51 2.20 
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PABPC1 Polyadenylate-binding protein 1 18 28 2.49 3.74 
MEF2B Myocyte-specific enhancer factor 
2B 
7 7 2.3 3.25 
RBMXL1 RNA binding motif protein, X-
linked-like-1 
4 26 2.29 2.4 
GATAD2B cDNA FLJ37346 fis, clone 
BRAMY2021310, highly similar to 
Transcriptional repressor p66 beta 
9 11 2.17 2.02 
PABPC4 Polyadenylate-binding protein 12 19 2.16 2.61 
YLPM1 YLP motif-containing protein 1 21 64 2.16 3.22 
CPSF3L Integrator complex subunit 11 4 4 2.11 2.45 
KHDRBS1 KH domain-containing, RNA-
binding, signal transduction-
associated protein 1 
14 47 2.09 3.00 
RBMX RNA-binding motif protein, X 
chromosome 
9 36 2.09 2.02 
TCF20 Transcription factor 20 23 24 2.07 2.21 
SMARCD2 SWI/SNF-related matrix-
associated actin-dependent 
regulator of chromatin subfamily 
D member 2 
5 5 2.05 2.60 
PHF14 PHD finger protein 14 14 15 2.05 2.21 
 620 







